Back to News

³Ô¹Ï±¬ÁÏ Announces Research Site
Clinical Trial Management System

Cloud CTMS software to improve research site efficiency and integrate seamlessly with sponsors

PLEASANTON, CA ¡ª April 1, 2025 ¡ª ³Ô¹Ï±¬ÁÏ Systems (NYSE: VEEV) today announced , a clinical trial management system for research sites that is integrated with and to allow sites to comprehensively manage clinical trials within one main system. Integration with sponsors using ³Ô¹Ï±¬ÁÏ¡¯s Clinical Platform gives sites seamless bidirectional data flow to sponsors to reduce manual processes and increase efficiency.

¡°We need to work efficiently to help more families enroll their children in studies and get lifesaving treatment,¡± said Theresa Oswald, director of research operations and conduct at Ann & Robert H. Lurie Children¡¯s Hospital of Chicago. ¡°In our experience, we have found that systems like ³Ô¹Ï±¬ÁÏ SiteVault with a CTMS provide a streamlined user experience. This can help drive speed for the benefit of our patients.¡±

¡°We are excited to bring ³Ô¹Ï±¬ÁÏ SiteVault CTMS to the industry,¡± said Nick Frenzer, general manager, site solutions at ³Ô¹Ï±¬ÁÏ. ¡°High-quality cloud software and seamless sponsor integration will help sites be more efficient. By making the SiteVault suite free for over 90% of research sites, we are doing our part as a Public Benefit Corporation to improve clinical research for sites and sponsors.¡±

³Ô¹Ï±¬ÁÏ SiteVault CTMS is planned for initial release in August 2025 and will be free for sites with up to 20 concurrent active studies. Learn more about ³Ô¹Ï±¬ÁÏ SiteVault CTMS and see a live demo during , April 24-27, in New Orleans.

Additional Information
For more on ³Ô¹Ï±¬ÁÏ¡¯s site solutions, visit
Connect with ³Ô¹Ï±¬ÁÏ on LinkedIn:

About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world¡¯s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

³Ô¹Ï±¬ÁÏ Forward-looking Statements
This release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ¡¯s products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at .

###

Contact:

Deivis Mercado
³Ô¹Ï±¬ÁÏ Systems
925-226-8821
deivis.mercado@veeva.com